These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Penicillamine nephropathy in rheumatoid arthritis. A clinical, pathological and immunological study. Bacon PA; Tribe CR; Mackenzie JC; Verrier-Jones J; Cumming RH; Amer B Q J Med; 1976 Oct; 45(180):661-84. PubMed ID: 1005658 [TBL] [Abstract][Full Text] [Related]
8. Longterm followup of treatment with D-penicillamine for rheumatoid arthritis: effectivity and toxicity in relation to HLA antigens. Moens HJ; Ament BJ; Feltkamp BW; van der Korst JK J Rheumatol; 1987 Dec; 14(6):1115-9. PubMed ID: 3437418 [TBL] [Abstract][Full Text] [Related]
9. Drug-induced anticentromere antibody? Haberhauer G; Bröll H Z Rheumatol; 1989; 48(2):99-100. PubMed ID: 2786663 [TBL] [Abstract][Full Text] [Related]
10. An assessment of penicillamine therapy in rheumatoid arthritis and the influence of previous gold therapy. Webley M; Coomes EN J Rheumatol; 1979; 6(1):20-4. PubMed ID: 439106 [TBL] [Abstract][Full Text] [Related]
11. Frequent induction of insulin autoantibodies by D-penicillamine in patients with rheumatoid arthritis. Vardi P; Brik R; Barzilai D; Lorber M; Scharf Y J Rheumatol; 1992 Oct; 19(10):1527-30. PubMed ID: 1464863 [TBL] [Abstract][Full Text] [Related]
13. [Tissue autoantibodies during therapy with levamisole for rheumatoid arthritis]. Cozzi F; Ruffatti A; Dalla Santa G; Dal Molin I; Fiocco U; Todesco S Boll Soc Ital Biol Sper; 1982 Apr; 58(7):407-11. PubMed ID: 6979345 [TBL] [Abstract][Full Text] [Related]
14. Factors affecting the development of penicillamine side-effects. Corke CF; Huskisson EC Rheumatol Rehabil; 1978 Feb; 17(1):34-7. PubMed ID: 310574 [TBL] [Abstract][Full Text] [Related]
15. HLA-DR antigens and proteinuria induced by aurothioglucose and D-penicillamine in patients with rheumatoid arthritis. Speerstra F; Reekers P; van de Putte LB; Vandenbroucke JP; Rasker JJ; de Rooij DJ J Rheumatol; 1983 Dec; 10(6):948-53. PubMed ID: 6420562 [TBL] [Abstract][Full Text] [Related]
16. Effects of D-penicillamine on inflammatory and immune reactions. Harth M; Keown PA; Orange JF Clin Invest Med; 1984; 7(1):45-51. PubMed ID: 6723124 [TBL] [Abstract][Full Text] [Related]
17. [Autoimmune phenomena in D-penicillamine therapy]. Kolarz G; Ludwig H; Sabeti M; Scherak O Acta Med Austriaca; 1975; 2(4):130-3. PubMed ID: 1083615 [TBL] [Abstract][Full Text] [Related]
18. Effects of D-penicillamine on circulating protein complexes in rheumatoid arthritis and primary biliary cirrhosis. Wollheim FA J Rheumatol Suppl; 1981; 7():74-9. PubMed ID: 7014877 [TBL] [Abstract][Full Text] [Related]
19. [Changes in various humoral immunity indicators during the treatment of rheumatoid arthritis with D-penicillamine (cuprenil)]. Chwalińska-Sadowska H; Małdykowa H; Zajaczek-Grabowska A; Dratwianka B; Abgarowicz-Miłkowska T; Swierczyńska Z; Orłowska G; Rdułtowska H; Luft S; Rogozińska E Reumatologia; 1981; 19(2):151-7. PubMed ID: 6459630 [No Abstract] [Full Text] [Related]
20. [Early recognition of adverse effects, especially of kidney lesions, in patients with progressive chronic polyarthritis under D-Penicillamine therapy]. Otto W; Pietruschka WD; Beenken O Z Gesamte Inn Med; 1975 Aug; 30(15):507-9. PubMed ID: 1189496 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]